USE OF PDE III INHIBITORS FOR THE TREAMENT OF ASYMPTOMATIC (OCCULT) HEART FAILURE

• US 20070112010A1
• Filed: 11/14/2006
• Published: 05/17/2007
• Est. Priority Date: 11/14/2005
• Status: Abandoned Application

• Current Assignee: Andrea Vollmar, Christian Troetschel, Rainer Kleeman
• Original Assignee: Andrea Vollmar, Christian Troetschel, Rainer Kleeman
• Inventors: Troetschel, Christian, Kleeman, Rainer, Vollmar, Andrea
• Application Number:
  US11/559,467
• Publication Number:
  US 20070112010A1
• Time in Patent Office: Days
• US Class Current: 514/252.160
• CPC Class Codes: A61K 31/4174 Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
• CPC Class Codes: A61K 31/4439 containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole nicotine A61K31/465
• CPC Class Codes: A61K 31/444 containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
• CPC Class Codes: A61K 31/50 Pyridazines; Hydrogenated pyridazines
• CPC Class Codes: A61K 31/501 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca²⁺-sensitizing agent or a pharmaceutically acceptable derivative thereof for the preparation of a medication for the prolongation of time until onset of clinical symptoms in patients having an asymptomatic (occult) heart failure or for the reduction of heart size in patients having an asymptomatic (occult) heart failure of a patient suffering from asymptomatic heart disease.

Claims

1. A method for reducing the size of a heart in a patient having an asymptomatic (occult) heart failure comprising administering a therapeutically effective amount of a phosphodiesterase type III (PDE III) inhibitor or a Ca²⁺-sensitizing agent or a pharmaceutically acceptable derivative thereof.

2. The method according to claim 1, wherein the asymptomatic (occult) heart failure is asymptomatic (occult) DCM.

3. The method according to claim 1 wherein the PDE III inhibitor additionally exhibits calcium sensitising effects.

4. The method according to claim 1 wherein the PDE III inhibitor or Ca²⁺-sensitizing agent is selected from the group consisting of pimobendan, milrinone, levosimendan, amrinone, enoximone, piroximone, and a pharmaceutically acceptable derivative thereof.

5. The method according to claim 1, wherein the PDE III inhibitor or Ca²⁺-sensitizing agent is utilized in oral or parenteral form.

6. The method according to claim 1, wherein the PDE III inhibitor or Ca²⁺-sensitizing agent is administered in a daily dose from 10 μ

g/kg to 10 mg/kg.

7. The method according to claim 1, wherein said patient is a mammal selected from the group consisting of primates including humans, dogs, cats and horses.

8. A method for prolongation of the time until onset of clinical symptoms in a patient having an asymptomatic (occult) heart failure comprising administering a therapeutically effective amount of a phosphodiesterase type III (PDE III) inhibitor or a Ca²⁺-sensitizing agent or a pharmaceutically acceptable derivative thereof.

9. The method according to claim 8, wherein the asymptomatic (occult) heart failure is asymptomatic (occult) DCM.

10. The method according to claim 8, wherein the PDE III inhibitor additionally exhibits calcium sensitizing effects.

11. The method according to claim 8, wherein the PDE II inhibitor or Ca²⁺-sensitizing agent is selected from the group consisting of pimobendan, milrinone, levosimendan, amrinone, enoximone, piroximun and a pharmaceutically acceptable derivative thereof.

12. The method according to claim 8, wherein the PDE II inhibitor or Ca²⁺-sensitizing agent is utilized in oral or parenteral form.

13. The method according to claim 8, wherein the PDE II inhibitor or Ca²⁺-sensitizing agent is administered in a daily dose from 10 μ

g/kg to 10 mg/kg.

14. The method according to claim 8, wherein the patient is a mammal selected from the group consisting of primates, dogs, cats and horses.